Weight Loss Drugs Are a Golden Ticket for Health-Linked Stocks
- Lilly, Novo, Viking Therapeutics among names that have rallied
- Investors see Novo trial on heart benefits as next catalyst
This article is for subscribers only.
New drugs that slim down patients are boosting the stocks of companies that may benefit from the next chapter in weight loss.
The medicines known as glucagon-like peptide agonists, or GLP-1s, are making waves with celebrity influencers as well as investors, sending shares of Eli Lilly & Co. and Novo Nordisk A/S soaring. WW International Inc., better known as WeightWatchers, also surged after a deal that would help people gain access to the drugs.